[Asia Economy Reporter Yoo Hyun-seok] Medipron is showing strong performance. It appears that the news of a high possibility of FDA approval for Aducanumab, an Alzheimer's treatment developed by the US biotech company Biogen, has had an impact.
As of 2:16 PM on the 2nd, Medipron was trading at 3,630 KRW, up 3.57% (125 KRW) compared to the previous trading day.
Medipron possesses MDR-1339, a dementia treatment targeting beta-amyloid. It operates via the same mechanism as Aducanumab but is known to have higher BBB (Blood Brain Barrier) permeability than antibody therapies.
Medipron's ‘MDR-1339’ works by inhibiting the aggregation of beta-amyloid, the causative protein of Alzheimer's dementia, and fundamentally blocking toxins that kill brain cells, thereby preventing and treating dementia through the beta-amyloid mechanism. It currently holds patents registered in the US, the UK, four European countries, and Japan.
A company official stated, “With the recent increased likelihood of Biogen's Aducanumab receiving FDA approval, an environment is being established where not only the resumption of domestic clinical trials for MDR-1339, which has superior Blood Brain Barrier permeability compared to antibody therapies, but also overseas clinical trials and license-out through partnering with multinational pharmaceutical companies can be considered.”
The dementia diagnostic kit ‘QPLEX Alz plus assay,’ jointly developed by Medipron and Quantamatrix, is preparing to apply for new medical technology evaluation within this year. Before using Aducanumab as an Alzheimer's treatment, a diagnostic product is needed for accurate diagnosis. Considering clinical results showing Aducanumab's excellent therapeutic effects in patients with mild dementia or mild cognitive impairment, the company explains that the usability and value of the ‘QPLEX Alz plus assay,’ which enables Alzheimer's diagnosis before symptom onset, are further enhanced.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
